The June edition of Editors’ Picks includes a clinical trial that clinched a new FDA approval for adagrasib, a new imaging modality to predict glioblastoma response, and more.
Patients given waivers to participate in A trial had outcomes the same or slightly better than people who met the standard requirements; findings support broader and more inclusive trial designs. Cancer patients sometimes find...
The FDA approved the immunotherapy epcoritamab-bysp for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to epcoritamab-bysp (Epkinly) for the treatment of adult patients with follicular...
The FDA issued its first approval for the use of A KRAS G12C inhibitor in a tumor type other than lung. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to adagrasib...
Risk for cancer and cardiovascular disease linked to air pollution, and three cancer drugs could face generic competition by 2028.
Learn about the types of cancer immunotherapy including immune checkpoint inhibitors, ACT, therapeutic vaccines, and more.
LGBTQ+ cancer survivors offer lessons learned, and a researcher explains the odds of chronic conditions in LGBTQ+ survivors.
Transgender and gender nonconforming people are most likely to have continuing conditions, regardless of age, race and ethnicity, smoking history, and socioeconomic status, according to A study. Of people who have survived cancer, those...
The FDA approved pembrolizumab, in combination with chemotherapy, for certain patients with endometrial cancer. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) plus the chemotherapies carboplatin and paclitaxel, followed by pembrolizumab...
The FDA approved the bispecific T-cell engager blinatumomab for use in the consolidation phase of therapy for certain patients with leukemia. The U.S. Food and Drug Administration (FDA) has approved blinatumomab (Blincyto) for use...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More